Receive The Newest Study Notifications

FibroGen, Inc. (FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA) in cancer patients...

Scientists at the University of Strathclyde researching a system to measure and monitor blood chemistry levels in premature and sick babies through their skin Scientists at the University of Strathclyde are researching a system to measure and monitor blood chemistry...

Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American Academy of Ophthalmology 2019...

-Patients treated at the high dose show impressive survival benefit--IL4R population surviving twice as long as current approved treatments- TORONTO and HOUSTON, Sept 25, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX:...

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo. “The...

Medtronic Continues to Invest in Scientific Evidence for Expansion of Indications and Greater Clinical Understanding of Infuse™ Bone Graft Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients in its Phase 2 trial of AG013 for the treatment of severe oral...

 Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its clinical activities. The Company reported that it is on track to complete its Clinical...

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke.  NSI-566 is...

d Journal of Medicine in 20181. Additionally, please visit the "CEO Letters" section of the Emmaus Life Sciences website to stay informed of corporate updates and remarks: https://www.emmausmedical.com/content/ceoletters/ceo-letter-sep-10-2019-193 Endari® Phase 3...

NESS ZIONA, Israel, Sept. 24, 2019 /PRNewswire/ -- Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, today announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the...

Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in its Phase 3 clinical...

Phase III BALANCE study now fully enrolled BLA submission anticipated in Q1 2020 through FDA accelerated approval pathway    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company...

Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today announced that MD Anderson Cancer Center ("MDACC") has completed enrolment and begun dosing the first cohort of three...

Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has surpassed 75% of...

Personalized Stem Cells, Inc. announces clinical trial sites qualified for FDA approved clinical trial for treatment of osteoarthritis with stem cells. Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has completed training and site...

Company to provide additional transport stability data points in response to FDA Clinical Hold Letter CMC clearance for VIITAL™ trial anticipated in Q4 2019 Investor conference call today, Monday, September 23 at 09:30 a.m. ET NEW YORK and CLEVELAND, Sept. 23, 2019...

Pre-Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health - CRP, LDL, total cholesterol, triglycerides, oxidized LDL, and blood pressure reduced - Interim results support excellent safety profile - Enrollment continues Cardax,...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune thrombocytopenia...